Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You are incorrect, cell therapy products do include cancer vaccines that include both autologous cells and allogeneic cells. Dendritic cell vaccines are included in these certifications.
The timing of this e-mail tells you everything you need to know about the intentions of this poster.
I cannot understand why this e-mail is being repeated considering that it is a deliberate attempt at sowing FUD on this board. This is not the type of e-mail any new investors need to see and I believe that it was intentionally shared after the recent 8K.
What we can all agree on is that at some point we will see DCVAX getting approved based on all the data we have seen so far. In my opinion this latest card played by LP is a warning to the market that she has the ability to go it alone even at .65c and no matter what ammunition the detractors may have to stall NWBO's progress the end outcome is certain. At some point the market will have to accept this and when that occurs proper valuation of NWBO tech will have a positive impact on the SP. Again all IMHO.
Glad to see you are being more genteel in your response.
In my original response to you I actually wrote this "A few may be given prior to loyal longs but the majority will be sold at much higher prices".
Anything I state is just an opinion. This board is a continuous opinion piece with a few scatterings of facts.
I respect your opinion but at the same time disagree. I think SP will start to rise over the coming weeks in anticipation of many positive events soon to be revealed. Again IMHO.
Here is what you actually stated.
"The only question is, will the dilution occur when the price is still down here in the $0.60's, or will it happen later after news and be less impactful? Obviously most here are of the latter opinion. I am of the former. Neither can be proven right or wrong at the moment so it is pointless to debate."
I AM OF THE FORMER. Dilution in the 60's. I think I can read.
You are completely incorrect that the C shares will be diluted at 65c. The C shares will be utilized post MAA news and journal/TLD. A few may be given prior to loyal longs but the majority will be sold at much higher SP. Your dreams of buying back in the 50's and lower are now just that a rapidly fading dream.
Yup, I agree 100% with you on this one as there is no way NWBO does not inform the world that they have completed and validated the EDEN project. This is the one piece of news that I am waiting for as it confirms the arrival of DCVAX as a viable project to meet any future demand that any dendritic cell vaccine may be applied to. We can almost say with certainty that DCVAX-L will be approved but until they confirm and approve the EDEN project there will most certainly be a supply bottleneck. I still firmly believe that once the EDEN project is complete a partnership/buyout is inevitable with Merck still being the front runner. EDEN is required to justify the price LP is probably asking for. All IMO.
If that was the case then that would be bigger news than the commercial license application itself as it validates DCVAX as a tour de forces with the ability to meet demand for more than just one application. If project EDEN is indeed complete and moving toward commercial validation I am sure they would be eager to share this news as it would blow a hole in all the doubters arguments regarding NWBO being able to meet demand. In my opinion Project EDEN validation increases the SP 10 fold right out the gate and the valuation in the minds of the market will increase exponentially once true understanding of the coming science hits the market.
Part of an email sent to all investors.
In total during the British Empire there were 120 wars spanning 170 countries. War with opposing factions seeking their freedom was common.
After all the British at one time controlled 26% of the world and as they used to say the sun never set on the British Empire.
There are many independence days the world over celebrating the end of British rule so no big deal at all.
My thinking is that the next article he writes on NWBO is where he will try to save face. He will point out that without acceptance of the new endpoints the trial would have failed and therefore his original assertion that the trial failed was correct. He will then reflect that now that the new endpoints have been accepted that the trial will now succeed. He will point out the failures of the original design but accept that because of the changing landscape with immunotherapies that OS was the only way to measure this particular trial.
I fully expect that the cabal that had earmarked failure with this trial are now covering and extending their long positions.
I do not expect any sharp down terms but upward mobility once the covering at these low prices is complete.
Just my opinion on where we stand with AF and his backers. Just remember money talks and all the talk will now be on the potential of the upside not the downside.
It could be July 26th the National All or Nothing Day, but I will go with July 18th The World Listening day and of course the Nelson Mandela International day. It's also fitting that this year it falls on a Monday.
A fitting day for the World's introduction to a true breakthrough in the treatment of cancer.
Hi Flip, as always thanks for keeping this board honest and well informed.
Dendritic cell vaccines are the future and will lead to cures of all kinds of diseases not just cancer. This will never get outdated as our immune systems are millions of years ahead of the competition and far more sophisticated than anything man can come up with. Tuning the immune system and aiding it in defeating disease is the way of the future. This is a true paradigm shift in the way we treat disease and personalized vaccines are the answer. Now about that EDEN project, it’s approval signals the true beginning and the beginning of the end of chemicals much to the chagrin of BP. IMO
Danish Dude has supposedly confirmed that they all attended today. Linda Liau may be on stage and not in photo's.
Danish Dude
Direct has always been what the BP world fears the most and it is no coincidence that there was a major effort to silence NWBO once data started to come out regarding D's potential. NWBO know as Doc has alluded that results from future Direct trials will indeed be quick. The combination of L and D is the paradigm shift the world has been waiting for. Fear not there is a plan and D is a big part of it.
IMO there are many sitting on the sidelines waiting for the final validation of the EDEN project. The validation of this device guarantees that DCVAX in any form can be used across all cancers and not just be limited to GBM.
Eliminating manufacturing concerns will pave the way forward for a paradigm shift in oncology care. Big money will respond in a big way and the fortunes of this company will change for ever.
I think you will find that any potential partners in the oncology space here in the US did not want NWBO to succeed. The technology on offer by NWBO is a paradigm shift and that means a paradigm shift in the bottom line of most of these competing technologies. It looks like these potential partners have been sitting on the sideline hoping that NWBO never figure out the manufacturing that takes this technology to the next level. It looks like NWBO's tenacity will prove them wrong and the cost of NWBO rises by the day. Dendritic cells are after all the generals of the immune system and their importance will soon be revealed to the world in the upcoming article. IMO.
I think you are correct on this as the British Government and in particular the Cambridge Triangle intend to be leaders in providing biologics as the next wave of advanced medicines with NWBO leading the way with Dendritic style treatments.
Superscript refers to 5. Tan. Clin Neuropharmacol. 2021;44:216
This references this specific research
14 Tan L, Peng J, Liu P, Wu Q. The Efficacy of Dendritic Cell Vaccine for Newly Diagnosed Glioblastoma: A Meta-analysis of Randomized Controlled Studies. Clin Neuropharmacol 2021;44:216-21. [PMID: 34767325 DOI: 10.1097/WNF.0000000000000452] [Reference Citation Analysis]
This links to the following research document and note this is research only for documents up to 2019. This is not referencing any unblinded data!!
The efficacy of dendritic cell vaccine for newly diagnosed glioblastoma remains controversial. We conduct a systematic review and meta-analysis to explore the influence of dendritic cell vaccine on treatment efficacy for newly diagnosed glioblastoma. We search PubMed, EMBASE, Web of science, EBSCO, and Cochrane library databases through December 2019 for randomized controlled trials assessing the efficacy and safety of dendritic cell vaccine for newly diagnosed glioblastoma. This meta-analysis is performed using the random effect model. Three randomized controlled trials are included in the meta-analysis. Overall, compared with control group for newly diagnosed glioblastoma, dendritic cell vaccine shows no substantial effect on median overall survival [standard mean difference, 0.11; 95% confidence interval (CI), -0.18 to 0.41; P = 0.45], median progression-free survival (standard mean difference, 0.12; 95% CI, -0.24 to 0.48; P = 0.50), progression-free survival rate [risk ratio (RR), 1.29; 95% CI, 0.82–2.04; P = 0.27], overall survival rate (RR, 1.29; 95% CI, 0.61–2.72; P = 0.50), or nervous system disorders (RR, 0.80; 95% CI, 0.59–1.08; P = 0.14). Dendritic cell vaccine may provide no obvious benefits for the newly diagnosed glioblastoma.
Agree, I think we see a gradual uptrend into publication and after that the gloves are off and there will be no stopping the train. A publication authored by 70 scientists and peer reviewed in a major journal will change the dynamics forever.
So what you are saying is that this treatment will cure GBM. You are having a laugh right.
For this theory to play out the next article from AF will be one where he asserts that he was right all long vs PFS and had the company not got agreement from the 4 RA's to change endpoints the trial would have failed. He will then say that now that the endpoints have been changed to OS and been accepted by all 4 RA's that the trial will now likely succeed.
We will then see a complete change in the direction of the SP as the cabal in effect will have conceded. To get to this point the cabal will need to have covered most of their short positions and that may have started May 10th.
NWBIO's website is clearly backing the presented TLD data and this was also available at their booth over ASCO.
Links to all presentations are provided on their website so they are officially backing up all statements made regarding the presentations.
They are not beholden to Fife until they officially seek a private placement which I suspect will come after publication.
TLD data has been officially presented and supported by NWBO. To continually say that this is not fact is just plain stupid IMO.
We are awaiting the Journal which hopefully arrives shortly.
Below is the press release on their website.
Press Release
05
JUN
2022
Northwest Biotherapeutics Announces Presentations On DCVax®-L Personalized Vaccines, Manufacturing and Scale-Up, and DCVax®-L Clinical Program
BETHESDA, Md., June 5, 2022 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that yesterday on June 4, 2022, in the Industry Expert Theater during the ASCO 2022 conference, Dr. Marnix Bosch made a presentation discussing the Company’s DCVax-L technology for personalized dendritic cell vaccines, the Sawston, UK facility, the manufacturing technology, the development of automation, and preparations for manufacturing scale-up. In addition, a video presentation about the DCVax®-L clinical program was screened in the Company’s exhibit booth in the ASCO Exhibit Hall.
These presentations are now available online at https://virtualtrials.org/dcvax
The Industry Expert Theater is not an official event of the ASCO Annual Meeting. It is not sponsored, endorsed or accredited by ASCO®, CancerLinq®, or Conquer Cancer® the ASCO Foundation. It is not CME-accredited.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The Company’s lead program is a 331-patient Phase III trial of DCVax®-L for newly diagnosed and recurrent Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an “orphan disease.” This Phase III trial reached data lock and top line data was recently presented. The Company has also developed DCVax®-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial and, as resources permit, plans to pursue Phase II trials. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.
Hi Flip,
Can you calculate what the actual total survival figures are for the overall trial. They have split survival across nGBM and rGBM for obvious reasons. No matter how you look at it DCVAX-L was responsible for long term survival across the board. Thanks
That's my take as well. Big news on the horizon.
Yo do not appreciate the hint obviously.
Joan Lappin never confronted the takedown of the stock itself.
Her words regarding the matter were as follows.
"The day of this announcement, it traded 77 million shares. Essentially it became a meme stock."
There is no better example of a massively shorted company as we experienced on TLD day. The question is, will the meme crowd recognize that the next great scientific discovery for all cancers is being attacked and discredited by short manipulators.
TLD revealed a huge advance in oncology and it is time that this message starts to be sung from the rooftops.
NWBO needs to step up its game and if the meme crowd are alerted to a massive fraud then they may act but in all reality we need NWBO management to step up and start promoting this extraordinary news to the world and not just to a roomful of people.
When it comes to evaluating small biotechs using an exchange is definitely not the place. Yesterday was a prime example and I am sure that Linda Powers and any potential suitors will base their valuations based on real world data not Wall Street.
Yesterday was an anomaly in my mind, onwards and upwards we will head to what will be considered a correct valuation of this company now that we have statistically significant results. I fully expect many shrewd investors large and small to start piling into this company over the coming weeks. Chin up, yesterday was a beautiful day for the world of oncology and the world will soon wake up to what's coming.
Now that topline is out and the data points towards approval this company has now become a golden opportunity for investors of all kinds. With TLD in hand what is stopping NWBO from attracting large investors into the fold or indeed any other large investors who may have been sitting on the sidelines waiting.
The future of this company is bright and currently the most undervalued biotech on the market.
Big money should be piling into this little company because if not what is stopping them.
100% agree and my wife and I are ecstatic about the trial outcome. Sky is the limit for DCVAX and I believe big waves are on the way. SP manipulation out the gate by the cabal will soon be a distant memory.
This cabal have been stock piling shares for years just for this type of moment to combat positive data so they can in all likelihood start covering at the expense of retail and the uneducated.
What we also have to remember is that all data being compared to including current SOC include all IDH types so data in their trials are over inflated.
DCVAX completely outperforms all previous datasets when it comes to being compared to actual GBM as now recognized by the science by even greater margins than are being shown.
I found my issue, site was looked at as a spam site by my security. Was logged into the meeting so saw the whole presentation just wanted to peruse the excellent outcomes in detail.
The link in that post does not work, can you share a working link for the board.